Eka Care partners with NVIDIA to develop India’s first offline-capable medical scribe. Discover how this AI-powered documentation solution brings secure, sovereign healthcare technology to remote clinics.
Pfizer announced positive progression-free survival results from BREAKWATER trial Cohort 3, showing BRAFTOVI combined with cetuximab and FOLFIRI achieves statistically significant and clinically meaningful progression-free survival improvement compared to chemotherapy alone in previously untreated BRAF V600E-mutant metastatic colorectal cancer patients.
European Commission approves Wegovy 7.2 mg for obesity treatment. Clinical trial shows 21% average weight loss with 84% from fat mass. Now available across EU.
FDA approves a new simplified monthly dosing schedule for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in combination with LAZCLUZE (lazertinib) for first-line treatment of EGFR-mutated advanced non-small cell lung cancer. The approval allows patients to transition to monthly injections as early as Week 5, significantly reducing clinic visits while maintaining consistent efficacy with the previously approved bi-weekly schedule. PALOMA-2 trial data demonstrated high objective response rates and a fivefold reduction in administration-related reactions compared to intravenous delivery.
Eli Lilly’s Retevmo (selpercatinib) has shown promising results as an adjuvant therapy for early-stage lung cancer. The Phase 3 LIBRETTO-432 trial revealed that Retevmo adjuvant therapy significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cancer (NSCLC), marking a breakthrough for this rare molecular subtype affecting 1-2% of lung cancer cases.
In a landmark announcement, Roche revealed that Gazyva (obinutuzumab) met its primary endpoint in the phase III MAJESTY trial for primary membranous nephropathy treatment. The trial data demonstrates superior clinical outcomes compared to tacrolimus, positioning Gazyva as a transformative therapy for patients with this chronic autoimmune kidney condition. With nearly 88,000 affected patients in the EU and over 96,000 in the US, primary membranous nephropathy represents a significant unmet medical need. Gazyva phase III results show the potential to become the first FDA and EMA-approved therapy specifically for this indication. The positive MAJESTY trial outcomes highlight Gazyva’s mechanism deep tissue B cell depletion via anti-CD20 targeting as an effective approach to halting disease progression and preserving kidney function in primary membranous nephropathy patients.
The European Commission has granted approval for Amgen’s UPLIZNA® (inebilizumab) as an add-on treatment for adults with generalized myasthenia gravis making it the first and only CD19-targeted therapy authorized in Europe for this rare, debilitating autoimmune muscle disease. The approval is backed by pivotal Phase 3 data from the landmark MINT trial.
Groundbreaking data from the KALOS and LOGOS trials reveal that Breztri (BGF) triple-therapy significantly outperforms standard dual-combination inhalers for uncontrolled asthma. Published in The Lancet Respiratory Medicine, the study confirms a 76mL improvement in lung function and a meaningful reduction in severe exacerbations, signaling a potential shift in the global standard of care.
Final data from the Phase III ALIGN study reveals that Vanrafia® (atrasentan) effectively slows eGFR decline in IgAN patients, even when combined with SGLT2 inhibitors. Novartis moves toward traditional regulatory approval in 2026.
Avantor, Inc. concludes fiscal 2025 with a strategic pivot. While facing a GAAP net loss due to significant impairment charges, CEO Emmanuel Ligner introduces the “Revival” initiative a comprehensive plan to modernize e-commerce, relaunch the VWR brand, and optimize go-to-market strategies for a “transition year” in 2026.
